Scottsdale’s Mayo Clinic still needs participants for clinical trials on breast and prostate cancer prevention treatments.
Mayo Clinic would like to add 40 females and 60 males from the Valley to the screening process for the trials, sponsored by the National Cancer Institute. The national selection process will close next spring.
The trial for females is designed to determine the most effective prevention of breast cancer between the already approved Tamoxifen and Raloxifene, used to treat osteoporosis.
"Raloxifene, otherwise known by its brand name Evista, has shown some promise in breast cancer prevention," said Lynn Boyer, a nurse and research coordinator at Mayo Clinic.
Participation is open to all post-menopausal women who are considered to be at high risk for developing breast cancer. "The most important factor is a family history of the disease," Boyer said.
"(The trial) is building upon the original Tamoxifen studies," said Dr. Tom Fitch, a Mayo Clinic oncologist who is running the study. "We want to see if Evista is better, or safer. If it proves to be either of those, we’ll present the trials to the FDA for approval."
Fitch and Boyer are also looking for about 60 Valley males to help determine if either the essential element selenium or vitamin E are effective in the prevention of prostate cancer. The study is open to white males over 55 years old, or black males over 50.
"We’d like to see more African-Americans because of the high occurrences of prostate cancer in that community," Boyer said.
If either selenium or vitamin E shows an ability to significantly reduce the occurrence of prostate cancer, the trial will be submitted for Food and Drug Administration endorsement.
Participants should be prepared for lengthy trials. "Those who sign up for the studies are making at least a five-year commitment," Fitch said.
• To enroll in the National Cancer Institute’s breast or prostate cancer prevention trials at Mayo Clinic, call Lynn Dodd at (480) 301-9875.
• For more information on the prostate trial, visit
• For more information on the breast cancer trial, visit